5-(3,5-Dichloro-pyridin-4-ylsulfanyl)-4-nitro-thiophene-2-carboxylic acid (3-methyl-1,1-dioxo-2,3-dihydro-1H-1lambda(6)-benzo[b]thiophen-6-yl)-amide

ID: ALA4127188

Chembl Id: CHEMBL4127188

PubChem CID: 126559339

Max Phase: Preclinical

Molecular Formula: C19H13Cl2N3O5S3

Molecular Weight: 530.44

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  CC1CS(=O)(=O)c2cc(NC(=O)c3cc([N+](=O)[O-])c(Sc4c(Cl)cncc4Cl)s3)ccc21

Standard InChI:  InChI=1S/C19H13Cl2N3O5S3/c1-9-8-32(28,29)16-4-10(2-3-11(9)16)23-18(25)15-5-14(24(26)27)19(30-15)31-17-12(20)6-22-7-13(17)21/h2-7,9H,8H2,1H3,(H,23,25)

Standard InChI Key:  YEZAUTQLDFTNCN-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA4127188

    ---

Associated Targets(Human)

USP7 Tchem Ubiquitin carboxyl-terminal hydrolase 7 (837 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
USP47 Tchem Ubiquitin carboxyl-terminal hydrolase 47 (99 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 530.44Molecular Weight (Monoisotopic): 528.9394AlogP: 5.65#Rotatable Bonds: 5
Polar Surface Area: 119.27Molecular Species: NEUTRALHBA: 8HBD: 1
#RO5 Violations: 2HBA (Lipinski): 8HBD (Lipinski): 1#RO5 Violations (Lipinski): 2
CX Acidic pKa: 12.32CX Basic pKa: 1.28CX LogP: 4.66CX LogD: 4.66
Aromatic Rings: 3Heavy Atoms: 32QED Weighted: 0.33Np Likeness Score: -1.31

References

1. Wu J, Kumar S, Wang F, Wang H, Chen L, Arsenault P, Mattern M, Weinstock J..  (2018)  Chemical Approaches to Intervening in Ubiquitin Specific Protease 7 (USP7) Function for Oncology and Immune Oncology Therapies.,  61  (2): [PMID:28768102] [10.1021/acs.jmedchem.7b00498]
2. Li P, Liu HM..  (2020)  Recent advances in the development of ubiquitin-specific-processing protease 7 (USP7) inhibitors.,  191  [PMID:32092586] [10.1016/j.ejmech.2020.112107]

Source